CASI Pharmaceuticals, Inc. (CASIF): Cost of Revenue
$10.64M
Year ended 2025-12-31
-12.4%
3-year compound annual growth
+2.3%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.64M | -38.8% | 2026-05-15, From 2025-01-01 |
| 2024-12-31 | $17.39M | +25.8% | 2026-05-15, From 2024-01-01 |
| 2023-12-31 | $13.83M | -12.6% | 2026-05-15, From 2023-01-01 |
| 2022-12-31 | $15.83M | +26.0% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $12.56M | +32.1% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $9.51M | n/a | 2023-04-26, From 2020-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $10.64M | -38.8% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $4.62M | +20.4% |
| Celularity Inc (CELU) | 2025-12-31 | $20.07M | +33.9% |
| uniQure N.V. (QURE) | 2025-12-31 | $1.69M | +33.1% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $2.39M | +402.7% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $7.04M | -17.6% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $10.35M | +26.3% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $6.64M | -14.5% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $857.0K | -28.6% |
Compare CASIF, EVFM, CELU, QURE side by side · Screen every company in Pharmaceutical Preparations ↗